Module 4

From Science to patients and customers

Business thinking for commercialisation and capturing value from data

DATE: 25 January 2024 (in person, 12.00pm to 17.00pm)

This session develops an initial roadmap for commercialising science to reach patients or other customers and debates the issues of innovating around human genomic data by:

  • Developing your understanding of the market landscape, customers and competitors and exploring when and how to engage with business-to-business or business to healthcare customers
  • Exploring the specific contexts of healthcare systems and pharmaceutical companies as partners and customers and the roles of the stakeholders that may influence your success
  • Understanding the importance of compelling vision and mission statements and how to craft these and clear objectives to guide your strategy
  • Navigating the complexity of innovating around human genomic data: legal considerations of creating, curating, storing, and accessing data and the ethical issues and why they matter 
  • Highlighting data creation strategies of building your own vs. partnering the resulting business models and how data is valued and priced in the context of data businesses.

 

Speakers

Lamprini Kaftantzi, Commercial Senior Advisor, Health Innovation East

Dr Kaftantzi is a senior advisor with the Commercial Team at Health Innovation East. In her role she focusses on supporting innovators/SMEs through their innovation journey and into the NHS as well as helping NHS providers with the implementation and evaluation of new technologies. Lamprini trained in biology and genetics before completing doctoral studies on the clinical and commercial translation of advanced cell therapies. She previously worked as a market access consultant and as a Health Technology Assessor of medical devises and diagnostics for one of NICE’s External Assessment Centres.

Brian Gladsden, CEO, Mosaic Therapeutics

Brian Gladsden has over 25 years’ experience in the biopharmaceutical industry and therapeutic leadership in oncology, specialty care, and general medicines. Most recently, he was the SVP and member of the Worldwide Leadership Team at Novartis Oncology, responsible for global commercialisation and strategy for a $16bn portfolio. He has been in various leadership positions, including Country CEO, leading cancer therapeutic development and commercial launch across the US, Europe, Australia, South Korea and Japan.

Mariam Makhmutova, Business Development Manager, GENXT

Mariam Makhmutova is a Business Development Manager at GENXT and has worked alongside the founding team to identify a market opportunity, develop a viable go-to-market strategy, and execute strategic partnerships. Mariam previously worked with healthtech startup and holds degrees from UCL and Imperial College London.

Sarion Bowers, Head of Policy, Wellcome Sanger Institute

Sarion Bowers is the Head of Policy at the Wellcome Sanger Institute. She completed her PhD in Biochemistry at the University of Cambridge before continuing her research in DNA packaging and gene regulation in the UK and the US. She changed careers and now specialises in science and technology policy relating to genomics. Sarion has a particular interest UK science policy, data protection and the ethical, legal and societal issues that arise from the use of genomics, including genome editing.

James Peach, CEO, Human Centric Drug Discovery

James is the CEO of Human Centric, an Oxford University spinout improving neurology drug discovery by bringing more human data to the process, backed by Oxford Science Enterprises. He has been at cutting edge of developing and commercialising genetics and healthcare data in the UK, since setting up Cancer Research UK’s Stratified Medicine Programme with AstraZeneca and Pfizer, and the parallel Stratified Medicine Innovation Platform with the Technology Strategy Board (now Innovate UK). He subsequently was a founding partner of Syncona, the Wellcome Trust’s venture capital arm, focussed on UK genetic and data opportunities. He joined Genomics England as first employee and Managing Director of the Main Programme, setting up the sequencing and sample acquisition operations of this national whole genome programme with Illumina and the NHS Genomics Medicine Service. He then worked in the Precision Medicine and Medicines Discovery Catapults, helping UK SMEs with access to samples and data for precision medicine, before starting his own companies.